OBJECTIVE: The authors sought to analyze the impact of a computerized physician order entry (CPOE) order form for enoxaparin sodium injection (Lovenox) to reduce the daily cost of drug therapy by switching appropriate patients to once-daily enoxaparin administration. METHODS: The study population included patients older than 18 years of age who had been treated with enoxaparin from September 1 to December 31, 2008 (the pre-order form implementation group) and from March 1 to June 30, 2009 (the post-order form implementation group). The wholesale acquisition cost was used to determine the cost of enoxaparin per day. Appropriate dosing was established by chart review. RESULTS: The post-implementation group showed a trend toward a higher cost of enoxaparin therapy per day compared with the pre-implementation group (P = 0.23). There was a non-significant increase in appropriate dosing after implementation of the order form-from 64.5% before implementation to 71.5% after implementation (P = 0.13). In the overall cohort, although the authors controlled for other factors that could influence cost, patients who received the appropriate dose per protocol were 3.2 times more likely (95% confidence interval, 1.8-5.9; P = 0.001) to have lower enoxaparin drug costs per day of therapy. CONCLUSION: The use of a CPOE enoxaparin order form did not reduce the daily cost of therapy.
OBJECTIVE: The authors sought to analyze the impact of a computerized physician order entry (CPOE) order form for enoxaparin sodium injection (Lovenox) to reduce the daily cost of drug therapy by switching appropriate patients to once-daily enoxaparin administration. METHODS: The study population included patients older than 18 years of age who had been treated with enoxaparin from September 1 to December 31, 2008 (the pre-order form implementation group) and from March 1 to June 30, 2009 (the post-order form implementation group). The wholesale acquisition cost was used to determine the cost of enoxaparin per day. Appropriate dosing was established by chart review. RESULTS: The post-implementation group showed a trend toward a higher cost of enoxaparin therapy per day compared with the pre-implementation group (P = 0.23). There was a non-significant increase in appropriate dosing after implementation of the order form-from 64.5% before implementation to 71.5% after implementation (P = 0.13). In the overall cohort, although the authors controlled for other factors that could influence cost, patients who received the appropriate dose per protocol were 3.2 times more likely (95% confidence interval, 1.8-5.9; P = 0.001) to have lower enoxaparin drug costs per day of therapy. CONCLUSION: The use of a CPOE enoxaparin order form did not reduce the daily cost of therapy.
Authors: D W Bates; G J Kuperman; E Rittenberg; J M Teich; J Fiskio; N Ma'luf; A Onderdonk; D Wybenga; J Winkelman; T A Brennan; A L Komaroff; M Tanasijevic Journal: Am J Med Date: 1999-02 Impact factor: 4.965
Authors: Philip Chen; Milenko J Tanasijevic; Ronald A Schoenenberger; Julie Fiskio; Gilad J Kuperman; David W Bates Journal: Am J Clin Pathol Date: 2003-03 Impact factor: 2.493
Authors: G Merli; T E Spiro; C G Olsson; U Abildgaard; B L Davidson; A Eldor; D Elias; A Grigg; D Musset; G M Rodgers; A A Trowbridge; R D Yusen; K Zawilska Journal: Ann Intern Med Date: 2001-02-06 Impact factor: 25.391
Authors: Robert A Harrington; Richard C Becker; Christopher P Cannon; David Gutterman; A Michael Lincoff; Jeffrey J Popma; Gabriel Steg; Gordon H Guyatt; Shaun G Goodman Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota Journal: Chest Date: 2008-06 Impact factor: 9.410